BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33259959)

  • 1. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
    Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
    Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
    Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
    Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
    Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U
    Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
    Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy.
    Ocasio JK; Babcock B; Malawsky D; Weir SJ; Loo L; Simon JM; Zylka MJ; Hwang D; Dismuke T; Sokolsky M; Rosen EP; Vibhakar R; Zhang J; Saulnier O; Vladoiu M; El-Hamamy I; Stein LD; Taylor MD; Smith KS; Northcott PA; Colaneri A; Wilhelmsen K; Gershon TR
    Nat Commun; 2019 Dec; 10(1):5829. PubMed ID: 31863004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
    Climans SA; Macdonald DR; Sutherland DE; Mason WP
    BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
    Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
    Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
    De Smaele E; Ferretti E; Gulino A
    Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
    Lou E; Nelson AC; Kool M
    Cancer Biol Ther; 2019; 20(11):1398-1402. PubMed ID: 31423907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered biomimetic nanoparticle for dual targeting of the cancer stem-like cell population in sonic hedgehog medulloblastoma.
    Kim J; Dey A; Malhotra A; Liu J; Ahn SI; Sei YJ; Kenney AM; MacDonald TJ; Kim Y
    Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24205-24212. PubMed ID: 32934143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
    Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
    J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
    Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
    [No Abstract]   [Full Text] [Related]  

  • 16. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib.
    Rudin CM
    Clin Cancer Res; 2012 Jun; 18(12):3218-22. PubMed ID: 22679179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis, and Structure-Activity Relationship of Tetrahydropyrido[4,3-d]pyrimidine Derivatives as Potent Smoothened Antagonists with in Vivo Activity.
    Lu W; Liu Y; Ma H; Zheng J; Tian S; Sun Z; Luo L; Li J; Zhang H; Yang ZJ; Zhang X
    ACS Chem Neurosci; 2017 Sep; 8(9):1980-1994. PubMed ID: 28618224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.